Guanhao Biotech(SZ:300238) Xin Lang Cai Jing·2025-11-12 02:53Core Viewpoint - Guanhao Biological Technology Co., Ltd. has shown a significant increase in stock price, reflecting positive market sentiment and potential growth in the regenerative medicine sector [1][2]. Company Overview - Guanhao Biological was established on October 22, 1999, and went public on July 6, 2011. The company is located in Huangpu District, Guangzhou, Guangdong Province [1]. - The main business areas include research, production, and sales of regenerative medical materials and medical implants, as well as cell therapy technology development, preparation, clinical application, and immune cell storage [1]. - The revenue composition of the company is as follows: medical devices account for 73.28%, pharmaceuticals 15.21%, and leasing and other services 11.51% [1]. Shareholder Information - Yongying Fund has a fund listed among the top ten circulating shareholders of Guanhao Biological. The Medical Device ETF (159883) entered the top ten circulating shareholders in the third quarter, holding 1.3128 million shares, which is 0.5% of the circulating shares [2]. - The Medical Device ETF (159883) was established on April 22, 2021, with a current scale of 4.73 billion. Year-to-date returns are 9.53%, ranking 3722 out of 4216 in its category, while it has experienced a 1.36% loss over the past year, ranking 3671 out of 3937 [2]. - The fund manager of the Medical Device ETF is Shu Kefa, who has been in the position for 2 years and 92 days, with a total fund asset scale of 6.282 billion. The best fund return during his tenure is 103.17%, while the worst is -30.27% [2].